Key Market Segments:
By Indication
-
Cancer
-
Cardiovascular Diseases
-
Neurological Diseases
-
Immunological Diseases
-
Others
By Technology
-
Diagnostics
-
Drug Discovery & Development
-
Personalized Medicine
-
Disease Risk Assessment
-
Others
By end-user
-
Pharmaceutical & Biotechnology Companies
-
Diagnostics & Research Laboratories
-
Hospitals & Specialty Clinics
-
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Turkey
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Predictive Biomarkers Market is projected to grow from USD 28.80 billion in 2025 to USD 156.85 billion by 2035, expanding at a CAGR of 18.47% during 2026–2035 due to rising adoption of precision medicine and targeted therapies.
Key growth drivers include increasing prevalence of chronic diseases, growing demand for personalized medicine, advancements in genomic sequencing technologies, and rising integration of biomarkers in drug development and clinical trials.
The cancer segment dominates the market, accounting for 46.82% of total revenue in 2025, primarily due to the widespread use of biomarkers in oncology for targeted therapy selection and immunotherapy guidance.
North America holds the largest market share, contributing about 42.63% of global revenue in 2025, driven by advanced healthcare infrastructure, strong pharmaceutical R&D capabilities, and widespread adoption of precision medicine.
Major companies operating in the market include Thermo Fisher Scientific, Illumina Inc., Roche Diagnostics, Qiagen N.V., Agilent Technologies, Abbott Laboratories, Siemens Healthineers, Guardant Health, Exact Sciences Corporation, and Natera Inc.